Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

No Longer Aiming To Partner At Proof-of-Concept, Flexion Raises $20M For Late-Stage Trials

This article was originally published in The Pink Sheet Daily

Executive Summary

Now focused on two key programs in its osteoarthritis portfolio, the Massachusetts drug developer will align itself for a more traditional exit rather than a Big Pharma partnership.

You may also be interested in...



Flexion’s Slow-Release Steroid Now On Faster Track With FDA

Following guidance from the agency on injectable osteoarthritis drug FX006, Flexion plans to file first with single-dose studies instead of waiting for longer-term data for repeated doses. This will speed up initial Phase III work by one year, the firm says.

Licensing Deals Still Backloaded In 2013, But Biotechs Could Gain Leverage

An analysis of alliance deals in 2013 shows pharmas’ continued reliance on heavily structured deals, a strategy that has often frustrated biotechs looking to partner. But the appetite for new IPO listings may be giving them more options, provoking competitive deal terms from licensors.

Reinventing Flexion For The World Beyond Proof-Of-Concept

Flexion Therapeutics had the pedigree, determination, and corporate connections to source and speed to clinical proof-of-concept its in-licensed pharma assets, and it planned to build a business around getting paid to do so. But a funny thing happened on the way to the bank.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS073685

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel